13.06.2017 • NewsCollaborationLuciano RossettiMerck & Co.

US Merck and F-star in Cancer Collaboration

US drugmaker Merck has signed a partnership agreement with UK biotech F-star to develop and commercialize five of the Cambridge-headquartered company’s novel bispecific immuno-oncology antibodies.

The deal includes F-star’s preclinical lead asset FS118, which is designed to block LAG-3 (Lymphocyte-Activation Gene 3) and PD-L1 (Programed Death-Ligand 1), two pathways commonly used by cancer cells to evade the immune system. F-star said a preclinical model shows that FS118 could improve efficacy compared to monotherapy combinations, supporting the potential to initiate a clinical development program. The other four antibodies target specific pathways to increase the anti-tumor immune response.

Under the agreement, Merck will spend up to €115 million in upfront, R&D and milestone payments in the first two years. The New Jersey-based company will make further payments upon exercising its option to acquire the antibodies, with the total value of the deal potentially reaching above €1 billion.

Commenting on the partnership, Luciano Rossetti, executive vice president and global head of R&D at Merck’s biopharma business, said: “Our collaboration with F-star will help us to rapidly enhance our pipeline and grow our portfolio of bispecific immunotherapies. This deal complements our internal capabilities in immuno-oncology and positions us as a potential leader in this important area of research.”

F-star’s CEO, John Haurum, added that the collaboration is a further validation of its bispecific antibody platform and underscores the attractiveness of its asset-centric business model. “This approach also provides us with additional non-dilutive cash to support our investment in the development of our own pipeline of bispecific antibodies, with a strong focus on immuno-oncology,” he said.

Company

Logo:

Merck & Co

126 East Lincoln Avenue
07065 Rahway
US

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.